ArticleBMC cancer2025
Comparative study of neoadjuvant chemoradiotherapy, chemotherapy, and chemoimmunotherapy for locally advanced esophageal squamous cell carcinoma.
Article in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThis study aimed to compare the efficacies of neoadjuvant chemoradiotherapy (NCRT), chemotherapy (NCT), and chemoimmunotherapy (NCIT) in patients with locally advanced esophageal squamous cell carcinoma (LAESCC). The primary objective was to assess the overall survival (OS) among the three treatment groups.
methodsA retrospective cohort of 625 patients treated at the Fourth Hospital of Hebei Medical University between 2016 and 2022 was analyzed. Patients received NCRT, NCT, or NCIT followed by radical esophagectomy. To adjust for confounding factors, inverse probability of treatment weighting (IPTW) was employed. Chi-square tests, Fisher's exact tests, and multivariate Cox survival analyses were used to assess prognostic factors and survival outcomes.
resultsBefore IPTW, significant differences in baseline characteristics were observed among the three groups. After IPTW adjustment, differences were mitigated, allowing for a balanced comparison. NCIT demonstrated superior 4-year OS rate (91.4%) compared with NCRT (60.4%) and NCT (62.5%). The addition of adjuvant therapy further improved survival outcomes.
conclusionsNCIT may offer superior survival benefits over NCRT and NCT in patients with LAESCC, particularly when combined with adjuvant chemoimmunotherapy (ACIT). These findings underscore the potential of immunotherapy in multimodal treatment of LAESCC and warrant further investigation in prospective clinical trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.